DFPLNH—the key sugar code for cell communication, a new era of precision medicine CAS: 64309-01-9

At the forefront of life sciences, scientists are increasingly realizing that in addition to the sequence information of DNA and RNA, there is another layer of sophisticated "sugar code" language in living organisms. Difucosyl-p-lacto-N-hexose (DFPLNH), as a core structural unit of fucosylated human milk oligosaccharides (HMO) with clear structure and specific functions, is the key molecule to decipher this language. It is not only an important participant in natural biological processes, but also a rising star in modern biomedicine, especially in the fields of disease diagnostic marker discovery, immune regulation and precision treatment.

Chemical Information

Chemical name: Difucosyl-p-lacto-N-hexose

Common name/English abbreviation: DFPLNH (Difucosyl-para-Lacto-N-hexaose)

Chemical formula: C₅₂H₈₈N₂O₃₉

Molecular weight: 1365.25 g/mol

CAS number: 64309-01-9

Structural features: sophisticated three-dimensional identification “password”

DFPLNH is not a simple combination of sugar chains, its structure contains exquisite biological logic:

Core skeleton (lact-N-hexose): Taking "lact-N-hexose" as the basic skeleton, the structure itself is the core sequence of sugar chains in many human milk oligosaccharides and various cell surface glycosphingolipids and glycoproteins, and is the basis for complex glycoforms.

Key modification (fucosylation): Two fucosyl groups precisely connected at specific positions provide the “finishing” touch to functionality. Fucose is a deoxygenated six-carbon sugar, and its introduction completely changes the spatial conformation and chemical properties of the parent sugar chain.

Biological "code" function: This unique and deterministic difucose modification pattern forms a highly specific three-dimensional topology. This structure can be accurately recognized by specific lectins, antibodies or cell surface receptors (such as selectins). Like the matching of a lock and a key, it mediates a series of vital life activities such as cell-to-cell adhesion, immune signaling, and pathogen recognition.

Main applications and advantages

1. Unlocking the cellular communication code and empowering the next generation of disease biomarkers

In the process of various diseases such as cancer and inflammatory bowel disease, the glycosylation modification pattern on the cell surface will undergo significant and specific changes, among which the abnormal upregulation of fucosylation levels is one of the most common features.

Highly specific detection probe: DFPLNH, as a standard or antigen with a clear structure, can be used to develop highly sensitive and highly specific detection antibodies or lectin probes. These tools can accurately identify glycoproteins carrying the same or similar glycoform structure (such as alpha-fetoprotein AFP-L3, fucosylated variants of prostate-specific antigen PSA) in blood, tissue or secretions, enabling early diagnosis, prognosis assessment and recurrence monitoring of the disease.

A new dimension in liquid biopsy: In the field of liquid biopsy, DFPLNH-related antibodies can be used to capture and identify specific glycoform exosomes or glycoproteins in the circulation system, providing a new dimension beyond genetic mutations for non-invasive diagnosis.

2. Innovate core raw materials for the development of carbohydrate drugs and vaccines

Drug development based on sugar structures is a new track with great potential, and DFPLNH provides a clear molecular blueprint for this.

Pathogen infection inhibitors: Many bacteria and viruses (such as Helicobacter pylori, norovirus, influenza virus) initiate infection by recognizing fucosylated sugar chains on the host cell surface (such as Lewis b antigen, whose core structure contains DFPLNH analogues). DFPLNH and its derivatives can be used as competitive inhibitors or haptens for vaccine design to block pathogen adhesion and develop new anti-infective therapies.

Development of immunomodulators: Human milk oligosaccharides have been proven to regulate infant immunity and promote the growth of probiotics. As one of the active ingredients with a defined structure, DFPLNH is an ideal starting point for studying its immune regulatory mechanisms (such as regulating dendritic cell function, T cell response) and developing prebiotics or therapeutic oligosaccharide drugs that mimic its functions.

Precise construction of synthetic vaccines: In the field of synthetic sugar vaccines, DFPLNH can be used as a key sugar antigen unit, chemically or enzymatically linked to carrier proteins or peptides, to construct well-defined glycoconjugate vaccines targeting specific cancers or pathogens, overcoming the problem of batch-to-batch inconsistency of traditional polysaccharide vaccines.

3. Powerful tools and standards for basic research

Research on glycobiological mechanisms: DFPLNH is a high-quality standard substrate or product for studying the enzymatic properties, substrate specificity and catalytic mechanism of fucosyltransferases (FUTs, such as FUT2, FUT3). At the same time, it is also a key ligand molecule for analyzing the structure-function relationship of receptor proteins (such as lectins) that interact with it.

Preparation of glycochips: By immobilizing high-purity DFPLNH on the chip surface, functional glycochips can be prepared for high-throughput screening of proteins, antibodies or whole cells that bind to them, accelerating drug target discovery and molecular interaction network analysis.

Analytical method development and quality control: In the fields of glycomic analysis and biopharmaceuticals, DFPLNH can be used as an internal reference standard for liquid chromatography or mass spectrometry analysis, for qualitative and quantitative analysis of sugar chain structures in complex samples, and as a quality control reference for the glycosylation homogeneity of therapeutic antibodies.

Conclusion

Difucosyl-p-lacto-N-hexose (DFPLNH) is much more than a complex sugar molecule. It is a clearly identifiable character in the "sugar code" of life and a bridge molecule between basic discovery and clinical application. From revealing new mechanisms of disease occurrence and development to developing the next generation of highly specific diagnostic reagents; from designing new inhibitors to block infection to constructing well-defined synthetic vaccines, the precision glycoscience represented by DFPLNH is opening a door full of infinite possibilities for precision medicine.

The above information is provided by the editor of KASONS and is for scientific research only.